News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,018 Results
Type
Article (41592)
Company Profile (463)
Press Release (658963)
Section
Business (208392)
Career Advice (2002)
Deals (35941)
Drug Delivery (92)
Drug Development (83301)
Employer Resources (169)
FDA (16325)
Job Trends (15043)
News (352079)
Policy (32978)
Tag
Academia (2619)
Alliances (50599)
Alzheimer's disease (1273)
Approvals (16250)
Artificial intelligence (139)
Bankruptcy (361)
Best Places to Work (11732)
Biotechnology (349)
Breast cancer (123)
Cancer (1111)
Cardiovascular disease (102)
Career advice (1671)
Cell therapy (247)
Clinical research (65992)
Collaboration (405)
Compensation (199)
COVID-19 (2590)
C-suite (100)
Data (1138)
Diabetes (156)
Diagnostics (6197)
Earnings (86042)
Employer resources (147)
Events (112903)
Executive appointments (313)
FDA (16865)
Funding (362)
Gene therapy (191)
GLP-1 (610)
Government (4408)
Healthcare (18995)
Infectious disease (2674)
Inflammatory bowel disease (113)
Interviews (308)
IPO (16571)
Job creations (3694)
Job search strategy (1428)
Layoffs (439)
Legal (7928)
Lung cancer (174)
Manufacturing (181)
Medical device (13322)
Medtech (13327)
Mergers & acquisitions (19430)
Metabolic disorders (423)
Neuroscience (1564)
NextGen Class of 2024 (6733)
Non-profit (4532)
Northern California (1494)
Obesity (242)
Opinion (198)
Patents (102)
People (57620)
Phase I (20678)
Phase II (29132)
Phase III (21545)
Pipeline (458)
Postmarket research (2590)
Preclinical (8877)
Radiopharmaceuticals (251)
Rare diseases (233)
Real estate (5998)
Regulatory (21955)
Research institute (2403)
Resumes & cover letters (351)
Southern California (1323)
Startups (3746)
United States (13802)
Vaccines (565)
Weight loss (182)
Date
Today (136)
Last 7 days (801)
Last 30 days (3823)
Last 365 days (36674)
2024 (33592)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (200)
Asia (38508)
Australia (6402)
California (3407)
Canada (1289)
China (252)
Colorado (146)
Connecticut (160)
Europe (83982)
Florida (458)
Georgia (116)
Illinois (351)
Indiana (198)
Kansas (99)
Maryland (588)
Massachusetts (2711)
Michigan (159)
Minnesota (277)
New Jersey (965)
New York (965)
North Carolina (754)
Northern California (1494)
Ohio (140)
Pennsylvania (848)
South America (1105)
Southern California (1323)
Texas (473)
Utah (92)
Washington State (371)
701,018 Results for "chinook therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
BioForest
Chinook Therapeutics to Present at Upcoming May 2023 Investor Conferences
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
April 27, 2023
·
1 min read
BioForest
Chinook Therapeutics to Present at Upcoming April 2023 Investor Conferences
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
April 11, 2023
·
1 min read
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
·
2 min read
·
Kate Goodwin
Drug Development
Novartis’ $3.2B Chinook Buy Pays Off with Promising Phase III IgAN Data
Following the recent Chinook Therapeutics acquisition, the Novartis experimental IgA nephropathy therapeutic atrasentan significantly reduced protein in the urine of patients compared to placebo.
October 31, 2023
·
2 min read
·
Tristan Manalac
BioForest
Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Chinook Therapeutics, Inc. today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 3:20 pm ET, as well as 1x1 meetings.
March 7, 2023
·
1 min read
Business
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.
May 9, 2023
·
11 min read
Drug Development
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
Chinook Therapeutics, Inc. today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.
July 28, 2023
·
10 min read
BioForest
Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.
March 28, 2023
·
1 min read
Business
Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors.
April 13, 2023
·
5 min read
1 of 70,102
Next
